Kodiak Sciences Inc Common Stock (KOD) News
Latest headlines that mention KOD, newest first · each headline opens the original publisher
- Last price
- $94.26
- Day change
- +3.49%
- Next earnings
- 2026-11-12
KOD headlines
last 30 daysThe biotech is developing innovative therapies for people with eye diseases.
The trial tested two experimental eye drugs, Zenkuda and tabirafusp-ted, for treating wet age-related macular degeneration.
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea. The post Why This Regeneron Eye Rival Just Catapulted More Than 170% appeared first on Investor's Business Daily .
Also mentioned with KOD
30dHeadlines that tag both tickers
KOD news alerts
Get an alert by email or push when a new headline mentions KOD.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.